241 related articles for article (PubMed ID: 22538135)
21. Investigation of the Physico-Chemical Properties that Enable Co-Formulation of Basal Insulin Degludec with Fast-Acting Insulin Aspart.
Havelund S; Ribel U; Hubálek F; Hoeg-Jensen T; Wahlund PO; Jonassen I
Pharm Res; 2015 Jul; 32(7):2250-8. PubMed ID: 25563978
[TBL] [Abstract][Full Text] [Related]
22. Insulin and Lispro Insulin: What is Common and Different in their Behavior?
Selivanova OM; Suvorina MY; Surin AK; Dovidchenko NV; Galzitskaya OV
Curr Protein Pept Sci; 2017; 18(1):57-64. PubMed ID: 27226198
[TBL] [Abstract][Full Text] [Related]
23. In vitro stability of insulin lispro in continuous subcutaneous insulin infusion.
DeFelippis MR; Bell MA; Heyob JA; Storms SM
Diabetes Technol Ther; 2006 Jun; 8(3):358-68. PubMed ID: 16800757
[TBL] [Abstract][Full Text] [Related]
24. Role of a novel excipient poly(ethylene glycol)-b-poly(L-histidine) in retention of physical stability of insulin in aqueous solutions.
Taluja A; Bae YH
Pharm Res; 2007 Aug; 24(8):1517-26. PubMed ID: 17385016
[TBL] [Abstract][Full Text] [Related]
25. Stability of insulin lispro in insulin infusion systems.
Lougheed WD; Zinman B; Strack TR; Janis LJ; Weymouth AB; Bernstein EA; Korbas AM; Frank BH
Diabetes Care; 1997 Jul; 20(7):1061-5. PubMed ID: 9203437
[TBL] [Abstract][Full Text] [Related]
26. Urinary detection of rapid-acting insulin analogs in healthy humans.
Judák P; Coppieters G; Lapauw B; Van Eenoo P; Deventer K
Drug Test Anal; 2020 Nov; 12(11-12):1629-1635. PubMed ID: 32386349
[TBL] [Abstract][Full Text] [Related]
27. 14-day in vitro chemical stability of insulin lispro in the MiniMed Paradigm pump.
Sharrow SD; Glass LC; Dobbins MA
Diabetes Technol Ther; 2012 Mar; 14(3):264-70. PubMed ID: 22107252
[TBL] [Abstract][Full Text] [Related]
28. Existence of different structural intermediates on the fibrillation pathway of human serum albumin.
Juárez J; Taboada P; Mosquera V
Biophys J; 2009 Mar; 96(6):2353-70. PubMed ID: 19289061
[TBL] [Abstract][Full Text] [Related]
29. An ultrafast insulin formulation enabled by high-throughput screening of engineered polymeric excipients.
Mann JL; Maikawa CL; Smith AAA; Grosskopf AK; Baker SW; Roth GA; Meis CM; Gale EC; Liong CS; Correa S; Chan D; Stapleton LM; Yu AC; Muir B; Howard S; Postma A; Appel EA
Sci Transl Med; 2020 Jul; 12(550):. PubMed ID: 32611683
[TBL] [Abstract][Full Text] [Related]
30. [From the concept of fast acting analogs to the properties of the insulin Lispro].
Selam JL
Diabetes Metab; 1997 Sep; 23 Suppl 3():45-9. PubMed ID: 9410552
[TBL] [Abstract][Full Text] [Related]
31. Comparison of in vitro stability for insulin aspart and insulin glulisine during simulated use in insulin pumps.
Senstius J; Poulsen C; Hvass A
Diabetes Technol Ther; 2007 Dec; 9(6):517-21. PubMed ID: 18034606
[TBL] [Abstract][Full Text] [Related]
32. Mucoadhesive polyelectrolyte microparticles containing recombinant human insulin and its analogs aspart and lispro.
Balabushevich NG; Pechenkin MA; Zorov IN; Shibanova ED; Larionova NI
Biochemistry (Mosc); 2011 Mar; 76(3):327-31. PubMed ID: 21568867
[TBL] [Abstract][Full Text] [Related]
33. The continuing quest for better subcutaneously administered prandial insulins: a review of recent developments and potential clinical implications.
Owens DR; Bolli GB
Diabetes Obes Metab; 2020 May; 22(5):743-754. PubMed ID: 31930670
[TBL] [Abstract][Full Text] [Related]
34. Comparison of the effect of insulin glulisine to insulin aspart on breakfast postprandial blood glucose levels in children with type 1 diabetes mellitus on multiple daily injections.
Cemeroglu AP; Kleis L; Wood A; Parkes C; Wood MA; Davis AT
Endocr Pract; 2013; 19(4):614-9. PubMed ID: 23425652
[TBL] [Abstract][Full Text] [Related]
35. Adsorption of insulin with varying self-association profiles to a solid Teflon surface--influence on protein structure, fibrillation tendency and thermal stability.
Jorgensen L; Bennedsen P; Hoffmann SV; Krogh RL; Pinholt C; Groenning M; Hostrup S; Bukrinsky JT
Eur J Pharm Sci; 2011 Apr; 42(5):509-16. PubMed ID: 21352910
[TBL] [Abstract][Full Text] [Related]
36. Nasal absorption of mixtures of fast-acting and long-acting insulins.
Pillion DJ; Fyrberg MD; Meezan E
Int J Pharm; 2010 Mar; 388(1-2):202-8. PubMed ID: 20080164
[TBL] [Abstract][Full Text] [Related]
37. Comparison of insulin aspart and lispro: pharmacokinetic and metabolic effects.
Homko C; Deluzio A; Jimenez C; Kolaczynski JW; Boden G
Diabetes Care; 2003 Jul; 26(7):2027-31. PubMed ID: 12832307
[TBL] [Abstract][Full Text] [Related]
38. BioChaperone Lispro versus faster aspart and insulin aspart in patients with type 1 diabetes using continuous subcutaneous insulin infusion: A randomized euglycemic clamp study.
Heise T; Meiffren G; Alluis B; Seroussi C; Ranson A; Arrubla J; Correia J; Gaudier M; Soula O; Soula R; DeVries JH; Klein O; Bode B
Diabetes Obes Metab; 2019 Apr; 21(4):1066-1070. PubMed ID: 30565407
[TBL] [Abstract][Full Text] [Related]
39. Photoacoustic imaging reveals mechanisms of rapid-acting insulin formulations dynamics at the injection site.
Khadria A; Paavola CD; Maslov K; Valenzuela FA; Sperry AE; Cox AL; Cao R; Shi J; Brown-Augsburger PL; Lozano E; Blankenship RL; Majumdar R; Bradley SA; Beals JM; Oladipupo SS; Wang LV
Mol Metab; 2022 Aug; 62():101522. PubMed ID: 35671972
[TBL] [Abstract][Full Text] [Related]
40. Novel insulins: expanding options in diabetes management.
Gerich JE
Am J Med; 2002 Sep; 113(4):308-16. PubMed ID: 12361817
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
